Ariad Pharmaceuticals' Loss Shrinks 23% as Iclusig Revenue Rises

Ariad takes its first steps to rebuilding confidence with shareholders with a 23% reduction in losses heralded by a rise in Iclusig revenue and a reduction in R&D costs.

May 7, 2014 at 12:31PM

Controversial small-cap biopharmaceutical company Ariad Pharmaceuticals (NASDAQ:ARIA) took steps in the right direction to rebuilding its Iclusig brand this morning with the release of its first-quarter earnings results.

For the quarter, total revenue surged 82% to $11.8 million and included $8 million in sales of its leukemia drug Iclusig -- which was temporarily pulled from markets late last year for a couple of weeks and relabeled with more inclusive safety warnings – up 25% from the prior year. Per its press release, $4.7 million in sales came from the U.S. and $3.3 million from Europe. Ariad also noted $3.1 million in deferred revenue not yet reported, including $1.3 million in inventory waiting to be shipped from pharmacies to patients, and $1.8 million shipped to France despite the fact that reimbursement pricing negotiations are still ongoing.

In addition to product revenue, Ariad recorded $3.8 million in licensing revenue reflecting a $3.75 million milestone payment from Medinol for the licensing of ridaforolimus.

Research and development expenses shrank considerably during the quarter, partially as a result of the clinical hold placed on Iclusig by the FDA last year. R&D costs totaled just $28.6 million, down 31% from the prior-year period, as a reduction in clinical-trial costs, primarily the absence of its EPIC trial, which was shelved in October, led to the lower costs. Selling, general and administrative costs jumped 7% to $31.6 million and reflect the marketing effort put toward relaunching Iclusig at home and in new countries abroad.

Net loss for the quarter, inclusive of higher sales and lower costs, dipped 23% to $49.8 million, or $0.27 per share, from $64.7 million, or $0.36 per share in the year-ago period. Ariad announced that it ended the quarter with $183 million in cash and cash equivalents, down from $237.2 million in the sequential fourth quarter. 

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information